Visit Adherence and Visual Acuity in Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2)

References

• Retinal Vein Occlusions PPP 2019. American Academy of ophthalmology. Published October 11, 2019. Accessed July 14, 2022. https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp
   Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125(1):57–65. doi:10.1016/j.ophtha.2017.07.014.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179–1187. doi:10.1016/j.oret.2018.06.004.
   PubMedGoogle Scholar
• Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single anti–VEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125(4):522–528. doi:10.1016/j.ophtha.2017.10.010.
   PubMed Web of Science ®Google Scholar
• Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol Auckl NZ. 2014;8:1611–1621. doi:10.2147/OPTH.S60893.
   PubMedGoogle Scholar
• VanderBeek BL, Shah N, Parikh PC, Ma L. Trends in the care of diabetic macular edema: analysis of a national cohort. PLoS One. 2016;11(2):e0149450. doi:10.1371/journal.pone.0149450.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Hussain RM, Taraborelli D, Pollack JS, Williams DF. Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes. Ophthalmol Retina. Published online April 2, 2022:S2468-6530(22)00150-6. doi:10.1016/j.oret.2022.03.021.
   Google Scholar
• Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From access to engagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS. 2010;24(10):607–613. doi:10.1089/apc.2010.0086.
   PubMed Web of Science ®Google Scholar
• Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis. 2009;48(2):248–256. doi:10.1086/595705.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Youmans E, Jj G, Duffus WA. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study. AIDS Res Hum Retroviruses. 2010;27(7):751–758. doi:10.1089/aid.2010.0268.
   Web of Science ®Google Scholar
• Ramakrishnan MS, Yu Y, VanderBeek BL. Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial. JAMA Ophthalmol. 2020;138(3):237–242. doi:10.1001/jamaophthalmol.2019.4577.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Yu Y, VanderBeek BL. Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet Protocol T. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. Published online September 30, 2020;259(6):1419–1425. 10.1007/s00417-020-04944-w.
   Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al. SCORE2 report 2: study design and baseline characteristics. Ophthalmology. 2017;124(2):245–256. doi:10.1016/j.ophtha.2016.09.038.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Yu Y, VanderBeek BL. Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet Protocol T. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2021;259(6):1419–1425. doi:10.1007/s00417-020-04944-w.
   PubMed Web of Science ®Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072–2087. doi:10.1001/jama.2017.4568.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022.
   PubMed Web of Science ®Google Scholar
• Ehlken C, Helms M, Böhringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol Auckl NZ. 2018;12:13–20. doi:10.2147/OPTH.S151611.
   PubMed Web of Science ®Google Scholar